A fundamental analysis of Strides Arcolab Ltd. (STAR) covering revenue trends, profitability, valuation, and shareholding patterns.
Strides Arcolab Revenue Trend
Strides Arcolab Ltd. clocked ₹4,624 Cr in revenue for FY2025, up 13.0% from FY2024.
On a 10-year view, revenue grew at 14.5% annually from ₹1,196 Cr to ₹4,624 Cr. Healthy growth, and clearly ahead of the broader market.
At ₹4,624 Cr in annual revenue, Strides Arcolab Ltd. is one of the mid-sized players in the pharmaceuticals space.
Revenue has moved in the same direction for 3 years running, suggesting the growth trend has structural legs.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹4,624 Cr | +13.0% |
| FY2024 | ₹4,091 Cr | +8.3% |
| FY2023 | ₹3,779 Cr | +18.0% |
| FY2022 | ₹3,202 Cr | -3.4% |
| FY2021 | ₹3,316 Cr | — |
View Strides Arcolab Ltd.'s full 10-year revenue trend with CAGR analysis →
Strides Arcolab Profitability
Earnings per share (diluted) were ₹390.50 in FY2025, up from ₹-7.77.
Is Strides Arcolab Undervalued
The P/E Ratio approach puts Strides Arcolab Ltd.'s intrinsic value at ₹967, a 10.6% downside from the current market price.
Strides Arcolab Ltd. shares are currently trading at ₹1,081.20.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹967 | 10.6% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Strides Arcolab Ltd. with detailed assumptions →
Strides Arcolab Shareholding Pattern
A stable promoter holding of 27.9% over 4 quarters suggests the management group is comfortable with its position.
FII ownership stands at 28.7%, up from the 28.0% recorded a year ago.
Domestic institutional investors (DIIs) held 14.4% as of March 2026, up from 13.3% a year ago.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 27.9% | 28.7% | 14.4% | 28.9% |
| Dec 2025 | 27.9% | 29.5% | 13.0% | 29.6% |
| Sep 2025 | 27.9% | 28.5% | 13.0% | 30.6% |
| Jun 2025 | 28.3% | 28.0% | 13.3% | 30.4% |
Track quarterly shareholding changes for Strides Arcolab Ltd. →
Strides Arcolab Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
Total assets stood at ₹60.49B at the end of FY2025, up 3.6% from ₹58.40B a year earlier.
Inventories is the largest block at 21.1%, followed by Receivables at 19.9% and Other Assets at 18.7%.
Equity makes up 42.8% of liabilities and equity, with debt at 31.1% and operating liabilities at 26.2%. Over the year, debt is down 25.3% and equity is up 24.8%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 1.82B |
| Receivables | 12.03B |
| Inventories | 12.78B |
| Property, Plant & Equipment | 9.11B |
| Investments | 3.40B |
| Intangibles & Goodwill | 10.07B |
| Other Assets | 11.28B |
| Category | Value |
|---|---|
| Equity | 25.86B |
| Short-term Debt | 12.57B |
| Long-term Debt | 6.23B |
| Trade Payables | 10.32B |
| Other Liabilities | 5.50B |
Strides Arcolab Key Highlights
What should investors take away from Strides Arcolab Ltd.'s (STAR) latest numbers? Here's the summary.
Revenue of ₹4,624 Cr in FY2025, up 13.0% year-over-year.
Long-term revenue has been compounding at 14.5% annually over 10 years.
The company is profitable, with a net margin of 77.8% and net income of ₹3,598 Cr.
The P/E Ratio model implies 10.6% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
There's more to the story. Craytheon's full profile for Strides Arcolab Ltd. includes three valuation models, decade-long financials, and insider activity.